cariprazine

Also known as RGH 188, RGH-188, Vraylar®, trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochloride, Kariprazin

Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia and bipolar disorder. It is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. Cariprazine acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. It is a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatig

Key facts

Drug.image: Cariprazine.svg
Drug.image_class: skin-invert-image
Drug.width: 250
Drug.image2: Cariprazine ball-and-stick model.png
Drug.image_class2: bg-transparent
Drug.width2: 250
Drug.tradename: Vraylar, Reagila, Symvenu
Drug.DailyMedID: Cariprazine
Drug.licence_US: Cariprazine
Drug.pregnancy_AU: D
Drug.routes_of_administration: By mouth
Drug.class: Atypical antipsychotic
Drug.ATC_prefix: N05
Drug.ATC_suffix: AX15
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_UK: POM
Drug.legal_US: Rx-only

via Wikipedia infobox

Chemical data

Formula: C21H32Cl2N4O
Molecular weight: 427.4 g/mol
IUPAC name: 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
SMILES: CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl
InChIKey: KPWSJANDNDDRMB-UHFFFAOYSA-N
XLogP: 4.3
Polar surface area: 38.8 Å²
H-bond donors: 1
H-bond acceptors: 3
Formal charge: 0